Last reviewed 2026-05-14 · How we verify

DIFEBARBAMATE

Phase 2 active Small molecule

DIFEBARBAMATE is a difebarbamate drug. It is currently in Phase 2 development.

Difebarbamate is thought to work by modulating the activity of certain enzymes or receptors in the body.

Difebarbamate is a small molecule drug in the difebarbamate class, but its target and exact mechanism of action are unknown. It is not clear if it is FDA-approved or commercially available. There is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Further research is needed to understand its clinical applications and safety profile. As a result, it is difficult to provide a comprehensive summary of this drug.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DIFEBARBAMATE
Drug class	difebarbamate
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like a orchestra, and difebarbamate is like a conductor that helps the different cells work together in harmony. By influencing the activity of specific enzymes or receptors, difebarbamate may help to regulate various bodily functions. However, the exact details of how it works are still unclear.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DIFEBARBAMATE CI brief — competitive landscape report
DIFEBARBAMATE updates RSS · CI watch RSS

Frequently asked questions about DIFEBARBAMATE

What is DIFEBARBAMATE?

DIFEBARBAMATE is a difebarbamate drug.

How does DIFEBARBAMATE work?

Difebarbamate is thought to work by modulating the activity of certain enzymes or receptors in the body.

What drug class is DIFEBARBAMATE in?

DIFEBARBAMATE belongs to the difebarbamate class. See all difebarbamate drugs at /class/difebarbamate.

What development phase is DIFEBARBAMATE in?

DIFEBARBAMATE is in Phase 2.

Drug class: All difebarbamate drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing